Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 27, Issue 1, 2008, Pages 85-88

  Kang, C I ^a   Cheong, H S ^a   Chung, D R ^a   Peck, K R ^a   Song, J H ^a   Oh, M D ^b   Choe, K W ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE;

ADULT; ARTICLE; BACTEREMIA; CHOLANGITIS; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HEALTH CARE; HUMAN; INFECTION RISK; LIVER ABSCESS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 36649005520     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0401-6     Document Type: Article

References (12)

1. Bush K (2001) New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32:1085-1089
2. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657-686
3. Rodriguez-Bano J, Navarro MD, Romero L et al (2006) Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43:1407-1414
4. Rodriguez-Bano J, Navarro MD, Romero L et al (2004) Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase- producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:1089-1094
5. Colodner R, Rock W, Chazan B et al (2004) Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 23:163-167
6. Kang CI, Kim SH, Park WB et al (2004) Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574-4581
7. Friedman ND, Kaye KS, Stout JE et al (2002) Health care-associated bloodstream infections in adults: a reason to change the accepted definitions of community-acquired bacteremia. Ann Intern Med 137:791-797
8. Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G (2003) Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis 9:1024-1025
9. Chambers HF (2001) The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 8:178-182
10. Tomasz A (1999) New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am J Med 107:55S-62S
11. Pedersen G, Schonheyder HC, Steffensen FH, Sorensen HT (1999) Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia. J Antimicrob Chemother 43:119-126
12. Paterson DL, Ko WC, Von Gottberg A et al (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206-2212